Werbung
Werbung

ORIC

ORIC logo

Oric Pharmaceuticals, Inc. Common Stock

9.14
USD
Gesponsert
+0.69
+8.20%
09. Jan., 15:59 UTC -5
Geschlossen
exchange

Nach-Markt

9.21

+0.07
+0.72%

ORIC Ergebnisberichte

Positives Überraschungsverhältnis

ORIC übertreffen die 12 der letzten 23Schätzungen.

52%

Nächster Bericht

Datum des nächsten Berichts
16. Feb. 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.36
Implizierte Änderung von Q3 25 (Revenue/ EPS)
--
/
+9.09%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
--
/
-29.41%

Oric Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On 13. Nov. 2025, ORIC reported earnings of -0.33 USD per share (EPS) for Q3 25, beating the estimate of -0.41 USD, resulting in a 20.14% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +0.49% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 17 analysts forecast an EPS of -0.36 USD, with revenue projected to reach -- USD, implying an increase of 9.09% EPS, and increase of 0.00% in Revenue from the last quarter.
FAQ
For Q3 2025, Oric Pharmaceuticals, Inc. Common Stock reported EPS of -$0.33, beating estimates by 20.14%, and revenue of $0.00, 0% as expectations.
The stock price moved up 0.49%, changed from $12.19 before the earnings release to $12.25 the day after.
The next earning report is scheduled for 16. Feb. 2026.
Based on 17 analysts, Oric Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.36 and revenue of -- for Q4 2025.
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung